Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Federico Bolognani has been named vice president and head of clinical science at Axial Biotherapeutics. Most recently, Bolognani was vice president and head of clinical science at VectivBio.
Rogers Luo, former global vice president and general manager of Gilead Sciences’ China division, has been appointed president and general manager for greater China at Brii Biosciences. The company also appointed Ankang Li to the role of chief financial officer. Li was most recently the chief financial officer at Terns Biopharmaceuticals.
Zubin Eapen has been named chief medical officer of Element Science. Prior to this appointment, Eapen was chief medical officer of Anthem’s CareMore Health subsidiary.
Emmes has found its newest president and CEO in Christine Dingivan, who was formerly senior executive and head of global drug development at Novartis.
ERS Genomics has named Michael Arciero vice president of intellectual property and commercial development. Previously, Arciero was director of technology commercialization and new ventures for the Stevens Center for Innovation.
Veena Viswanath has been appointed vice president of translational biology and drug discovery at Escient Pharmaceuticals. Prior to this appointment, Viswanath served as executive director of research biology at Allergan.
European Laboratory Research & Innovation Group
Melanie Leveridge has been named chair of the European Laboratory Research & Innovation Group UK, a nonprofit organization. Leveridge currently serves as head of screening, profiling and mechanistic biology UK and global compound management at GlaxoSmithKline.
Gene therapy company Genprex has appointed Thomas Gallagher senior vice president of intellectual property and licensing. Gallagher comes from IP and licensing consultancy firm the Fenagh Group, where he served as principal.
Jordan Zwick, former chief strategy officer at clinical-stage biopharmaceutical company InflaRx, has been promoted to the position of chief strategy officer.
LEO Pharma has appointed Becki Morison executive vice president of global therapeutic and value strategy. Morison was most recently vice president of U.S. immunology at Eli Lilly.
Former chief operating officer of miRagen, Lee Rauch, has been named CEO of the company.
Nicox has named José Boyer, current vice president and head of clinical development, as interim head of R&D while the company searches for a permanent replacement for this role.
Novus Therapeutics has tapped David-Alexandre Gros as the company’s new CEO. Gros was most recently CEO of Imbria Pharmaceuticals. Novus Therapeutics has also named Steven Perrin, former CEO of Novus-acquired Anelixis, as president and chief scientific officer.
Madhavan Balachandran has been named chief operating officer of Nutcracker Therapeutics. Balachandran will continue to serve as a director of Catalent, uniQure, A2 Biotherapeutics and the Stevanato Group.
Obsidian Therapeutics has filled its previously vacant chief scientific officer role with the hiring of Jan ter Meulen, the former chief scientific officer at Immune Design.
Sean Bohen has been named president and CEO of Olema Oncology. Bohen currently serves as nonexecutive director of Gyroscope Therapeutics.
Praxis Precision Medicines
Praxis Precision Medicines has appointed Nicole Sweeny to the role of chief commercial officer. Sweeny served as franchise head/U.S. general manager at Takeda Pharmaceutical prior to this appointment. Praxis also brought on a new senior vice president of regulatory and quality, a role assumed by Alyssa Wyant, the former senior vice president of regulatory affairs at EryDel.
Former chief commercial officer of Raremark, Jeremy Edwards, has been appointed CEO of the company. Raremark’s head of product, Alex Garner, is set to assume the now-vacant chief commercial officer role.
Regulatory Compliance Associates
Regulatory Compliance Associates has appointed Steven Lynn as executive vice president of pharmaceuticals. Lynn most recently served as an independent life sciences consultant.
Repertoire Immune Medicines
Anthony Coyle has been named president of R&D at Repertoire Immune Medicines. Coyle was most recently the co-founder, president and CEO of Pandion Therapeutics.
William Sargent has been appointed senior vice president of commercial strategy for Venatorx Pharmaceuticals. Sargent most recently served as vice president of commercial strategy at Nabriva.
WCG Clinical has named Carsten Henke senior vice president of Europe and managing director of Germany. Henke comes to WCG from MediWound, where he served as chief commercial officer of Europe and managing director of the Germany and Europe operations.
Leonard Blum has been tapped by Calif.-based XWPharma to become the company’s new CEO. Most recently, Blum held a consulting commercial executive position at Madrigal Pharmaceuticals.